All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tezepelumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AMG 157
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
Tezepelumab, a potential first-in-class medicine, when added to standard of care (SoC) achieved a 56% reduction (p<0.001) in AAER over 52 weeks in the overall patient population, compared to placebo when added to SoC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tezepelumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AMG 157
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The 48-week trial did not meet the primary endpoint of a statistically significant reduction in the daily OCS dose, without loss of asthma control, with tezepelumab compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Silicon Valley Bank
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 23, 2020
Details:
The non-dilutive capital provides further financial flexibility to support pre-commercialization activities for ensifentrine, the Company’s first-in-class product candidate, Ensifentrine, which is currently in Phase 3 trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
If successful, the data will support the submission of a New Drug Application in the U.S. for nebulized ensifentrine for the maintenance treatment of COPD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
Ensifentrine meaningfully improved COPD symptoms in only 4 weeks, with the largest effect on breathlessness, across two different assessment tools, the E-RS™: COPD breathlessness subscale and the Transitional Dyspnea Index (TDI)*.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
